B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Clinical trials for B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 explained in plain language.
Never miss a new study
Get alerted when new B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 trials appear
Sign up with your email to follow new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise against aggressive leukemia
Disease control OngoingThis study tests a powerful mix of chemotherapy drugs plus a targeted pill (ponatinib) for people with a fast-growing leukemia called Philadelphia chromosome-positive ALL. The goal is to see if this combination can stop the cancer from coming back. About 88 adults with newly diag…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Promising new combo therapy for leukemia patients shows potential in major trial
Disease control OngoingThis study is for adults aged 18 to 75 with a specific type of leukemia called BCR-ABL-positive acute lymphoblastic leukemia (ALL). It compares the usual treatment (steroids, a targeted drug, and chemotherapy) with the same treatment plus an extra drug called blinatumomab. The go…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New combo therapy shows promise for older leukemia patients
Disease control OngoingThis study tested a combination of the immunotherapy drug blinatumomab with either standard chemotherapy or dasatinib and prednisone in adults aged 65 and older with acute lymphoblastic leukemia (ALL). The goal was to see if the combination could improve survival and control the …
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
Promising combo tackles Hard-to-Treat leukemia
Disease control OngoingThis early-phase study tests a new combination of drugs, including venetoclax, for adults with a specific type of leukemia (Ph+ ALL) that is either newly diagnosed or has returned. The main goal is to find the safest dose and see how well the treatment works. About 20 participant…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 08, 2026 13:04 UTC
-
Liver shield: nutrient may prevent chemo side effect in young leukemia patients
Symptom relief OngoingThis study tests whether adding levocarnitine, a natural nutrient, to standard chemotherapy can prevent severe liver damage in teens and young adults (ages 15-39) with leukemia or lymphoma. About 440 participants will receive either chemotherapy alone or chemotherapy plus levocar…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Symptom relief
Last updated Jun 15, 2026 19:02 UTC